SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- MedWaves' AveCure microwave coagulation-ablation (MWA) system uses microwave energy to volumetrically coagulate-ablate (destroy) soft-tissue lesions (abnormal structures) safely, effectively, precisely and with repeatability. The system has successfully treated over one-thousand patients worldwide, including lesions in bone, kidney, liver, lung and pancreas. The Company plans to bring its technology to treat lesions in other locations in the body. The Company's technology makes available treatment options for many cancer patients in either early or late stage and helps those who are running out of options.
People's Republic of China, with over 1.3 billion in population, is an important market for MedWaves. Every year, 2.6 million Chinese people are diagnosed with cancer, and 1.8 million deaths result from it. Cancer became the number-one cause of death among all illnesses in China in 2009. Lung and liver cancers are the leading cause of cancer deaths in China, and the Company is pleased to receive SFDA approval to import and sell its products to help those in need. MedWaves will work in close coordination with its Chinese distributor-partners to schedule and conduct clinical evaluations for the sale of its AveCure system in key hospitals in China. Earlier this year, Hong Kong University published its successful treatment of tumors in the liver using the MedWaves AveCure microwave ablation system. The Hong Kong University has adopted MedWaves Avecure system as a cancer treatment tool.
About AveCure Microwave Coagulation-Ablation System and Devices:
MedWaves AveCure Microwave Coagulation-Ablation System overcomes the limitations of other microwave and radiofrequency (RF) thermal ablation technologies to destroy lesions safely, effectively, precisely and with repeatability and uniformity. It is the only system approved in the market to provide clinicians with patented fully integrated real-time temperature, both forward and reverse-power feedback to control energy delivery intelligently. The system, which consists of a generator, extension cable set, and an array of single-patient-use microwave-probe devices, enables the surgeons and interventional radiologists to treat soft-tissue lesions, such as tumors, safely and easily, with confidence. This single-patient-use device provides a continuous revenue stream. MedWaves AveCure Microwave Coagulation-Ablation System has also received USFDA approval for sales in the United States and CE mark for sales in Europe. Other received approval and certification announcements to follow.
About MedWaves, Incorporated
MedWaves, Inc., a United States company based in San Diego, California, develops innovative and proprietary microwave ablation technology for the minimally invasive coagulation-ablation products for soft tissue lesions, such as tumors. The Company's management team has extensive experience in the medical device marketplace. The Company's proprietary technology allows for the development of minimally invasive microwave antenna devices in a wide range of sizes, shapes and flexibility to meet the clinicians' requirements in the treatment of lesions in bone, kidney, liver, lung, pancreas and other locations in the body.
Theodore Ormsby (email: email@example.com)
George Leung, PhD (email: firstname.lastname@example.org)
16760 W Bernardo Drive, San Diego, CA 92127, Tel: 858-946-0015, Website: http://www.medwaves.com
This press release was issued through eReleases(R). For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.
SOURCE MedWaves, Incorporated